本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CITIUS ONCOLOGY INC

0.9175
+0.00750.82%
盤後0.93000.0125+1.36%17:40 EDT
成交量:13.83萬
成交額:12.76萬
市值:8,531.03萬
市盈率:-1.86
高:0.9500
開:0.8900
低:0.8900
收:0.9100
52周最高:2.25
52周最低:0.4912
股本:9,298.12萬
流通股本:1,820.48萬
量比:1.75
換手率:0.76%
股息:- -
股息率:- -
每股收益(TTM):-0.4931
每股收益(LYR):-0.3380
淨資產收益率:-126.58%
總資產收益率:-29.12%
市淨率:2.11
市盈率(LYR):-2.71

資料載入中...

公司資料

公司名字:
CITIUS ONCOLOGY INC
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
11 Commerce Drive,First Floor,Cranford,New Jersey,United States
郵編:
07016
電話:
傳真:
- -
簡介:
Citius Oncology, Inc.(前身為TenX Keane Acquisition)於2021年3月1日在開曼群島註冊成立,並於2024年8月5日作為特拉華州公司遷移並歸化。Citius Oncology將作為一個平台,開發和商業化新型靶向腫瘤療法。2024年8月,其主要資產LYMPHIR獲得FDA批准,用於治療至少接受過一次全身治療的複發或難治性CTCL成人患者。

董事

名稱
職位
Leonard Mazur
Chairman of the Board, Chief Executive Officer and Director
Carol Webb
Independent Director
Dennis M. McGrath
Independent Director
Eugene Holuka
Independent Director
Joel Mayersohn
Independent Director
Jonathan Peri
Independent Director
Myron Holubiak
Director and Secretary
Robert J. Smith
Independent Director
Suren Dutia
Independent Director and Lead Independent Director

股東

名稱
職位
Leonard Mazur
Chairman of the Board, Chief Executive Officer and Director
Jaime Bartushak
Chief Business Officer and Chief Financial Officer
Myron Holubiak
Director and Secretary
Myron S. Czuczman
Chief Medical Officer and Executive Vice President